Share Price and Basic Stock Data
Last Updated: October 20, 2025, 8:48 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Dhampur Bio Organics Ltd operates primarily in the sugar industry, with its most recent market price standing at ₹81.6 and a market capitalization of ₹541 Cr. The company’s revenue from operations has shown variability over recent quarters, with sales recorded at ₹2,408 Cr for the fiscal year ending March 2023, a notable increase from ₹1,564 Cr in the previous fiscal year. However, the sales for the fiscal year ending March 2024 declined to ₹1,864 Cr, reflecting an ongoing challenge in maintaining revenue momentum. Quarterly sales figures further illustrate this trend, with a peak of ₹803 Cr in March 2023, followed by a drop to ₹583 Cr in June 2023. The company’s operating profit margin (OPM) fluctuated significantly, reporting 14% in March 2023 but dropping to 0% in the most recent quarter. This inconsistency in revenue and profitability highlights the challenges faced in the competitive sugar market, where pricing and demand can be volatile.
Profitability and Efficiency Metrics
Profitability metrics for Dhampur Bio Organics Ltd indicate a mixed performance. The net profit for the fiscal year ending March 2025 was reported at ₹15 Cr, a decrease from ₹46 Cr in March 2024 and ₹111 Cr in March 2023. The earnings per share (EPS) also reflected this trend, declining to ₹2.21 in March 2025 from ₹7.00 in March 2024. The company’s return on equity (ROE) stood at 1.56%, while the return on capital employed (ROCE) was at 3.97%, both of which are considerably low compared to industry standards. The interest coverage ratio (ICR) of 2.06x indicates a moderate ability to meet interest obligations, though it suggests potential pressure as it is lower than desirable levels. Furthermore, the cash conversion cycle (CCC) was recorded at 270 days, indicating room for improvement in operational efficiency, particularly in managing inventory and receivables.
Balance Sheet Strength and Financial Ratios
Analyzing the balance sheet of Dhampur Bio Organics Ltd reveals a high level of indebtedness, with total borrowings amounting to ₹1,162 Cr against reserves of ₹945 Cr. The debt-to-equity ratio stood at 1.14, indicating that the company’s financing is heavily reliant on debt, which poses risks in periods of low profitability. The liquidity ratios reflect a current ratio of 1.14 and a quick ratio of 0.12, suggesting that while current liabilities can be covered, the company may face challenges in meeting short-term obligations without liquid assets. The price-to-book value (P/BV) ratio is at 0.43x, indicating that the stock is trading below its book value, which may suggest undervaluation or concerns regarding future earnings potential. Overall, while the company maintains a substantial asset base, its reliance on debt financing and low liquidity ratios could constrain operational flexibility.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dhampur Bio Organics Ltd reveals a significant promoter holding of 50.79%, which indicates strong control by the founding members. However, foreign institutional investors (FIIs) have reduced their stake to 0.43%, down from 7.37% in September 2022, reflecting declining investor confidence. Domestic institutional investors (DIIs) hold a steady 0.45%, while public shareholding stands at 48.33%, with a total of 49,005 shareholders. The decline in FII participation may signal concerns over the company’s financial performance and market volatility. Furthermore, the company’s dividend payout ratio has increased to 56% in March 2025, suggesting a commitment to returning capital to shareholders, although this may also limit reinvestment in growth initiatives. The shifting dynamics in shareholding could impact future capital raising efforts and investor sentiment.
Outlook, Risks, and Final Insight
If margins sustain and operational efficiency improves, Dhampur Bio Organics Ltd could potentially stabilize its profitability despite recent fluctuations. The company faces risks from high debt levels and declining profitability, which may hinder growth unless managed effectively. Additionally, the volatility in sugar prices and changing regulatory environments present ongoing challenges that could impact revenue stability. Conversely, if the company can leverage its strong promoter backing to implement strategic initiatives aimed at cost reduction and market expansion, it may regain investor confidence and enhance financial performance. The focus on enhancing operational efficiencies and managing debt will be critical for navigating the competitive landscape of the sugar industry and improving overall returns for shareholders.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dhampur Bio Organics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gayatri Sugars Ltd | 109 Cr. | 14.7 | 21.4/7.02 | 683 | 11.4 | 0.00 % | 36.6 % | % | 10.0 |
| Dhampure Speciality Sugars Ltd | 69.6 Cr. | 83.5 | 142/82.0 | 22.5 | 41.0 | 0.00 % | 11.6 % | 8.88 % | 10.0 |
| Dhampur Bio Organics Ltd | 509 Cr. | 76.8 | 141/57.3 | 152 | 1.63 % | 3.97 % | 1.56 % | 10.0 | |
| DCM Shriram Industries Ltd | 1,526 Cr. | 176 | 214/142 | 17.6 | 103 | 1.14 % | 13.7 % | 11.8 % | 2.00 |
| Davangere Sugar Company Ltd | 496 Cr. | 3.47 | 12.9/3.03 | 43.9 | 2.45 | 0.00 % | 6.70 % | 3.17 % | 1.00 |
| Industry Average | 1,801.04 Cr | 265.48 | 52.96 | 229.21 | 0.64% | 8.62% | 7.89% | 6.37 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 496 | 515 | 594 | 803 | 583 | 538 | 280 | 463 | 467 | 466 | 464 | 464 | 526 |
| Expenses | 464 | 493 | 559 | 687 | 543 | 519 | 284 | 382 | 434 | 476 | 448 | 369 | 524 |
| Operating Profit | 32 | 22 | 34 | 116 | 41 | 19 | -4 | 81 | 33 | -10 | 16 | 96 | 1 |
| OPM % | 6% | 4% | 6% | 14% | 7% | 4% | -2% | 18% | 7% | -2% | 3% | 21% | 0% |
| Other Income | 3 | 6 | 1 | 2 | 2 | 1 | 16 | 5 | 1 | 1 | -1 | 1 | 2 |
| Interest | 14 | 9 | 5 | 13 | 13 | 9 | 6 | 18 | 21 | 16 | 10 | 20 | 22 |
| Depreciation | 8 | 9 | 10 | 13 | 11 | 10 | 14 | 14 | 12 | 11 | 15 | 16 | 14 |
| Profit before tax | 12 | 11 | 20 | 92 | 18 | 0 | -8 | 54 | 1 | -35 | -10 | 61 | -33 |
| Tax % | 29% | 28% | 26% | 13% | 32% | 88% | -28% | 28% | 83% | -34% | -32% | 26% | -33% |
| Net Profit | 8 | 8 | 15 | 80 | 13 | 0 | -6 | 39 | 0 | -23 | -7 | 45 | -22 |
| EPS in Rs | 1.24 | 1.16 | 2.26 | 12.08 | 1.91 | 0.01 | -0.85 | 5.94 | 0.02 | -3.52 | -1.03 | 6.75 | -3.31 |
Last Updated: August 19, 2025, 8:10 pm
Below is a detailed analysis of the quarterly data for Dhampur Bio Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 526.00 Cr.. The value appears strong and on an upward trend. It has increased from 464.00 Cr. (Mar 2025) to 526.00 Cr., marking an increase of 62.00 Cr..
- For Expenses, as of Jun 2025, the value is 524.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 369.00 Cr. (Mar 2025) to 524.00 Cr., marking an increase of 155.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 96.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 95.00 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value appears to be declining and may need further review. It has decreased from 21.00% (Mar 2025) to 0.00%, marking a decrease of 21.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.00 Cr. (Mar 2025) to 22.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 61.00 Cr. (Mar 2025) to -33.00 Cr., marking a decrease of 94.00 Cr..
- For Tax %, as of Jun 2025, the value is -33.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Mar 2025) to -33.00%, marking a decrease of 59.00%.
- For Net Profit, as of Jun 2025, the value is -22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 45.00 Cr. (Mar 2025) to -22.00 Cr., marking a decrease of 67.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -3.31. The value appears to be declining and may need further review. It has decreased from 6.75 (Mar 2025) to -3.31, marking a decrease of 10.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:31 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 0 | 1,564 | 2,408 | 1,864 | 1,862 | 1,920 |
| Expenses | 0 | 1,381 | 2,203 | 1,724 | 1,727 | 1,817 |
| Operating Profit | -0 | 183 | 205 | 140 | 135 | 103 |
| OPM % | 12% | 8% | 8% | 7% | 5% | |
| Other Income | 0 | 8 | 11 | 20 | 2 | 3 |
| Interest | 0 | 30 | 41 | 45 | 67 | 68 |
| Depreciation | 0 | 31 | 41 | 49 | 54 | 56 |
| Profit before tax | -0 | 129 | 135 | 65 | 16 | -18 |
| Tax % | 0% | 21% | 18% | 29% | 6% | |
| Net Profit | -0 | 102 | 111 | 46 | 15 | -7 |
| EPS in Rs | 16.74 | 7.00 | 2.21 | -1.11 | ||
| Dividend Payout % | 0% | 0% | 21% | 36% | 56% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 8.82% | -58.56% | -67.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | -67.38% | -8.83% |
Dhampur Bio Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -46% |
| TTM: | -117% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: July 25, 2025, 1:27 pm
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Equity Capital | 66 | 66 | 66 | 66 | 66 |
| Reserves | 709 | 812 | 922 | 945 | 945 |
| Borrowings | 403 | 835 | 810 | 1,057 | 1,162 |
| Other Liabilities | 373 | 287 | 278 | 244 | 223 |
| Total Liabilities | 1,551 | 2,000 | 2,077 | 2,313 | 2,398 |
| Fixed Assets | 631 | 690 | 909 | 1,036 | 1,076 |
| CWIP | 7 | 78 | 36 | 13 | 79 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 913 | 1,232 | 1,132 | 1,263 | 1,242 |
| Total Assets | 1,551 | 2,000 | 2,077 | 2,313 | 2,398 |
Below is a detailed analysis of the balance sheet data for Dhampur Bio Organics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 66.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 66.00 Cr..
- For Reserves, as of Mar 2025, the value is 945.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 945.00 Cr..
- For Borrowings, as of Mar 2025, the value is 1,162.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 1,057.00 Cr. (Mar 2024) to 1,162.00 Cr., marking an increase of 105.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 223.00 Cr.. The value appears to be improving (decreasing). It has decreased from 244.00 Cr. (Mar 2024) to 223.00 Cr., marking a decrease of 21.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,398.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,313.00 Cr. (Mar 2024) to 2,398.00 Cr., marking an increase of 85.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,076.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,036.00 Cr. (Mar 2024) to 1,076.00 Cr., marking an increase of 40.00 Cr..
- For CWIP, as of Mar 2025, the value is 79.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Mar 2024) to 79.00 Cr., marking an increase of 66.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,242.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,263.00 Cr. (Mar 2024) to 1,242.00 Cr., marking a decrease of 21.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,398.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,313.00 Cr. (Mar 2024) to 2,398.00 Cr., marking an increase of 85.00 Cr..
However, the Borrowings (1,162.00 Cr.) are higher than the Reserves (945.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | -403.00 | -652.00 | -605.00 | 139.00 | 134.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 25 | 23 | 17 | 11 | |
| Inventory Days | 341 | 163 | 288 | 288 | |
| Days Payable | 54 | 33 | 37 | 29 | |
| Cash Conversion Cycle | 312 | 154 | 269 | 270 | |
| Working Capital Days | 56 | 24 | 33 | 21 | |
| ROCE % | 11% | 10% | 5% | 4% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.21 | 7.00 | 16.74 | 15.35 | 0.00 |
| Diluted EPS (Rs.) | 2.21 | 7.00 | 16.74 | 15.35 | 0.00 |
| Cash EPS (Rs.) | 10.33 | 14.46 | 22.84 | 20.06 | 0.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 152.39 | 152.35 | 148.93 | 132.16 | 116.73 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 152.39 | 152.35 | 148.93 | 132.16 | 116.73 |
| Revenue From Operations / Share (Rs.) | 280.39 | 280.83 | 362.63 | 232.10 | 0.00 |
| PBDIT / Share (Rs.) | 20.86 | 24.15 | 32.56 | 28.68 | 0.00 |
| PBIT / Share (Rs.) | 12.74 | 16.69 | 26.45 | 23.96 | 0.00 |
| PBT / Share (Rs.) | 2.37 | 9.86 | 20.30 | 19.43 | 0.00 |
| Net Profit / Share (Rs.) | 2.21 | 7.00 | 16.73 | 15.35 | 0.00 |
| NP After MI And SOA / Share (Rs.) | 2.21 | 7.00 | 16.73 | 15.35 | 0.00 |
| PBDIT Margin (%) | 7.43 | 8.59 | 8.97 | 12.35 | 0.00 |
| PBIT Margin (%) | 4.54 | 5.94 | 7.29 | 10.32 | 0.00 |
| PBT Margin (%) | 0.84 | 3.51 | 5.59 | 8.36 | 0.00 |
| Net Profit Margin (%) | 0.78 | 2.49 | 4.61 | 6.61 | 0.00 |
| NP After MI And SOA Margin (%) | 0.78 | 2.49 | 4.61 | 6.61 | 0.00 |
| Return on Networth / Equity (%) | 1.45 | 4.59 | 11.23 | 11.61 | 0.00 |
| Return on Capital Employeed (%) | 6.42 | 8.78 | 14.41 | 15.23 | 0.00 |
| Return On Assets (%) | 0.61 | 2.01 | 5.34 | 5.09 | 0.00 |
| Long Term Debt / Equity (X) | 0.23 | 0.17 | 0.17 | 0.11 | 0.12 |
| Total Debt / Equity (X) | 1.14 | 1.03 | 0.81 | 0.93 | 0.50 |
| Asset Turnover Ratio (%) | 0.79 | 0.84 | 1.18 | 0.86 | 0.00 |
| Current Ratio (X) | 1.14 | 1.19 | 1.31 | 1.28 | 1.46 |
| Quick Ratio (X) | 0.12 | 0.16 | 0.35 | 0.17 | 0.29 |
| Inventory Turnover Ratio (X) | 1.25 | 1.69 | 1.69 | 1.62 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 113.00 | 49.96 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 24.20 | 24.20 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -13.00 | 50.04 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 75.80 | 75.80 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.06 | 3.54 | 5.29 | 6.32 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 1.25 | 2.03 | 3.72 | 4.38 | 0.00 |
| Enterprise Value (Cr.) | 1553.77 | 1776.49 | 1647.22 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.83 | 0.95 | 0.68 | 0.00 | 0.00 |
| EV / EBITDA (X) | 11.22 | 11.08 | 7.62 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.23 | 0.40 | 0.39 | 0.00 | 0.00 |
| Retention Ratios (%) | -13.00 | 50.03 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 0.43 | 0.75 | 0.96 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.23 | 0.40 | 0.39 | 0.00 | 0.00 |
| EarningsYield | 0.03 | 0.06 | 0.11 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dhampur Bio Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 5. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 5. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.33. This value is within the healthy range. It has decreased from 14.46 (Mar 24) to 10.33, marking a decrease of 4.13.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 152.39. It has increased from 152.35 (Mar 24) to 152.39, marking an increase of 0.04.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 152.39. It has increased from 152.35 (Mar 24) to 152.39, marking an increase of 0.04.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 280.39. It has decreased from 280.83 (Mar 24) to 280.39, marking a decrease of 0.44.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.86. This value is within the healthy range. It has decreased from 24.15 (Mar 24) to 20.86, marking a decrease of 3.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.74. This value is within the healthy range. It has decreased from 16.69 (Mar 24) to 12.74, marking a decrease of 3.95.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.37. This value is within the healthy range. It has decreased from 9.86 (Mar 24) to 2.37, marking a decrease of 7.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For PBDIT Margin (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 10. It has decreased from 8.59 (Mar 24) to 7.43, marking a decrease of 1.16.
- For PBIT Margin (%), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 10. It has decreased from 5.94 (Mar 24) to 4.54, marking a decrease of 1.40.
- For PBT Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 10. It has decreased from 3.51 (Mar 24) to 0.84, marking a decrease of 2.67.
- For Net Profit Margin (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has decreased from 2.49 (Mar 24) to 0.78, marking a decrease of 1.71.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 8. It has decreased from 2.49 (Mar 24) to 0.78, marking a decrease of 1.71.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 15. It has decreased from 4.59 (Mar 24) to 1.45, marking a decrease of 3.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 8.78 (Mar 24) to 6.42, marking a decrease of 2.36.
- For Return On Assets (%), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 2.01 (Mar 24) to 0.61, marking a decrease of 1.40.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.23, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.14. This value exceeds the healthy maximum of 1. It has increased from 1.03 (Mar 24) to 1.14, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.84 (Mar 24) to 0.79, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has decreased from 1.19 (Mar 24) to 1.14, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.16 (Mar 24) to 0.12, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 4. It has decreased from 1.69 (Mar 24) to 1.25, marking a decrease of 0.44.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 113.00. This value exceeds the healthy maximum of 50. It has increased from 49.96 (Mar 24) to 113.00, marking an increase of 63.04.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 24.20. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 24.20.
- For Earning Retention Ratio (%), as of Mar 25, the value is -13.00. This value is below the healthy minimum of 40. It has decreased from 50.04 (Mar 24) to -13.00, marking a decrease of 63.04.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 75.80. This value exceeds the healthy maximum of 70. There is no change compared to the previous period (Mar 24) which recorded 75.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.06. This value is below the healthy minimum of 3. It has decreased from 3.54 (Mar 24) to 2.06, marking a decrease of 1.48.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 3. It has decreased from 2.03 (Mar 24) to 1.25, marking a decrease of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,553.77. It has decreased from 1,776.49 (Mar 24) to 1,553.77, marking a decrease of 222.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.95 (Mar 24) to 0.83, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is 11.22. This value is within the healthy range. It has increased from 11.08 (Mar 24) to 11.22, marking an increase of 0.14.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.23, marking a decrease of 0.17.
- For Retention Ratios (%), as of Mar 25, the value is -13.00. This value is below the healthy minimum of 30. It has decreased from 50.03 (Mar 24) to -13.00, marking a decrease of 63.03.
- For Price / BV (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.43, marking a decrease of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.23, marking a decrease of 0.17.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dhampur Bio Organics Ltd:
- Net Profit Margin: 0.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.42% (Industry Average ROCE: 8.62%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.45% (Industry Average ROE: 7.89%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.25
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.96)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.14
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.78%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Sugar | Sugar Mill Compound, Village & Post - Asmoli, Sambhal Dist. Uttar Pradesh 244304 | investors@dhampur.com http://www.dhampur.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay Kumar Goel | Chairman |
| Mr. Ashwani Kumar Gupta | Vice Chairman |
| Mr. Gautam Goel | Managing Director & CEO |
| Mr. Sandeep Kumar | Whole Time Director |
| Mrs. Bindu Vashist Goel | Non Executive Director |
| Mrs. Ruchika Amrish Mehra Kothari | Independent Director |
| Mr. Vishal Saluja | Independent Director |
| Mr. Samir Thukral | Independent Director |
| Mr. Kishor Shah | Independent Director |
FAQ
What is the intrinsic value of Dhampur Bio Organics Ltd?
Dhampur Bio Organics Ltd's intrinsic value (as of 21 October 2025) is 28.92 which is 62.34% lower the current market price of 76.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 509 Cr. market cap, FY2025-2026 high/low of 141/57.3, reserves of ₹945 Cr, and liabilities of 2,398 Cr.
What is the Market Cap of Dhampur Bio Organics Ltd?
The Market Cap of Dhampur Bio Organics Ltd is 509 Cr..
What is the current Stock Price of Dhampur Bio Organics Ltd as on 21 October 2025?
The current stock price of Dhampur Bio Organics Ltd as on 21 October 2025 is 76.8.
What is the High / Low of Dhampur Bio Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dhampur Bio Organics Ltd stocks is 141/57.3.
What is the Stock P/E of Dhampur Bio Organics Ltd?
The Stock P/E of Dhampur Bio Organics Ltd is .
What is the Book Value of Dhampur Bio Organics Ltd?
The Book Value of Dhampur Bio Organics Ltd is 152.
What is the Dividend Yield of Dhampur Bio Organics Ltd?
The Dividend Yield of Dhampur Bio Organics Ltd is 1.63 %.
What is the ROCE of Dhampur Bio Organics Ltd?
The ROCE of Dhampur Bio Organics Ltd is 3.97 %.
What is the ROE of Dhampur Bio Organics Ltd?
The ROE of Dhampur Bio Organics Ltd is 1.56 %.
What is the Face Value of Dhampur Bio Organics Ltd?
The Face Value of Dhampur Bio Organics Ltd is 10.0.